Int J Yosulela iDis.NgoJuni 20, 2021: S1201-9712 (21) 00520-8.doi: 10.1016/j.ijid.2021.06.031.Kwi-Intanethi ngaphambi kokuprinta.
Imvelaphi: Ii-antibodies ezingathathi hlangothi (NAbs) zibalulekile ukunqanda ukosuleleka kwakhona nge-COVID-19.Siqhathanise iimvavanyo ezimbini ezinxulumene ne-NAb, oko kukuthi, uvavanyo lwe-hemagglutination (HAT) kunye novavanyo lwe-replacement virus neutralization (sVNT).
Iindlela: Ukucaciswa kwe-HAT kwafaniswa ne-sVNT, kunye novelwano kunye nokuqina kwe-antibodies kwizigulane ezinobunzima bezifo ezahlukeneyo zavandlakanywa kwiqela lezigulane ze-71 kwi-4 kwiiveki ze-6 kunye ne-13 kwiiveki ze-16.Uvavanyo lwe-kinetic lwezigulane ezinezifo ezinzima zobunzima obuhlukeneyo lwenziwa kwiveki yokuqala, yesibini neyesithathu.
Iziphumo: Ubume be-HAT yi>99%, kwaye uvakalelo luyafana nolo lwe-sVNT, kodwa lungaphantsi kunolo lwe-sVNT.Inqanaba le-HAT lihambelana ngokufanelekileyo kunye nenqanaba le-sVNT (i-Spearman's r = 0.78, p <0.0001).Xa kuthelekiswa nezigulane ezinesifo esincinci, izigulane ezinezifo eziphakathi kunye nezinzima zine-HAT titers eziphezulu.I-6/7 izigulane ezigula kakhulu zine-titer> 1: 640 kwiveki yesibini yokuqala, ngelixa i-5/31 kuphela izigulane ezigulayo zine-titer> 1: 160 kwiveki yesibini yokuqala.
Isiphelo: Ekubeni i-HAT iyindlela elula kwaye engabizi kakhulu yokufumanisa, ifanelekile njengesalathisi se-NAb kwiindawo ezihlwempuzekileyo.
Ixesha lokuposa: Jun-25-2021